# A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

Source: https://onco.cc/trials/nct06530251/  
OnCo record `nct06530251` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Ivonescimab, Cadonilimab, Sintilimab in hepatocellular carcinoma, run by Akeso, now recruiting.

## Summary

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) is a phase 1/2 interventional study registered as NCT06530251 by Akeso, with 280 participants planned, started 2024-09-24 and due to reach its primary completion in 2026-06. Interventions recorded: AK112, Cadonilimab, AK127, AK130, Sintilimab Injection. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06530251
- Phase: 1/2
- Setting: A Phase Ib/II Study of AK112 in Combination Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC)
- Sponsor: Akeso
- Enrolled: 280

## Sources

- ClinicalTrials.gov NCT06530251: https://clinicaltrials.gov/study/NCT06530251

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Sintilimab](https://onco.cc/drugs/sintilimab/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct06530251.json